| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 214 | - |
| Late-stage development programs | 207 | - |
| Early-stage development and preclinical programs | 113 | - |
| Compensation and personnel costs | 187 | - |
| Depreciation and amortization | 7 | - |
| Impairment of long-lived assets | 0 | - |
| Interest income, net | -25 | - |
| Income tax expense | 0 | - |
| Other segment items | 71 | - |
| Partnership reimbursements | -99 | - |
| Net loss | -247 | -112 |
| Stock-based compensation expense | 45 | 31 |
| Depreciation and amortization | 7 | 5 |
| Noncash lease expense | 5 | 3 |
| Impairment of long-lived assets | 0 | 0 |
| Amortization of discounts on marketable securities | 10 | 7 |
| Other items, net | 2 | 0 |
| Receivable from collaboration partners (6 and 18 from a related party) | -9 | -5 |
| Other assets ( and 6 from a related party) | -5 | 1 |
| Accounts payable (29 and to a related party) | 24 | 11 |
| Deferred revenue ((214) and (20) to a related party) | -214 | -188 |
| Other liabilities | 12 | -12 |
| Net cash used in operating activities | -362 | -265 |
| Purchases of marketable securities | 679 | 514 |
| Proceeds from maturities of marketable securities | 858 | 615 |
| Proceeds from sales of marketable securities | 70 | 69 |
| Purchases of property and equipment | 1 | 1 |
| Net cash provided by (used in) investing activities | 248 | 169 |
| Proceeds from issuance of common stock (14 and 228 from a related party) | 150 | 142 |
| Proceeds from debt issuances, net | 49 | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 3 | 3 |
| Payments of employee taxes related to net settlement of equity awards | 0 | 0 |
| Net cash provided by financing activities | 202 | 194 |
| Net increase in cash, cash equivalents and restricted cash | 88 | 98 |
| Cash and cash equivalents at beginning of period | 153 | - |
| Cash and cash equivalents at end of period | 241 | - |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)